AZ nabs a positive study for Imfinzi plus tremelimumab in li...

After a long run of trial disappointments, AstraZeneca is celebrating a win for its immuno-oncology combination of Imfinzi plus tremelimumab in advanced liver cancer.

Gilead trumpets data with newly-bought magrolimab in blood c...

Just three months after acquiring Forty Seven for $4.9 billion, Gilead has reported positive data on magrolimab, the lead drug from the deal, at ASCO 2020.

Roche signs up with Oncimmune to explore immunotherapy respo...

Roche has doubled down on a partnership with UK biotech Oncimmune looking at how autoantibodies can affect patients’ clinical response to cancer immunotherapies.

Merck & Co squares up to Roche with Keytruda data in triple-...

Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good

Merck builds case for six-week Keytruda dosing as FDA starts...

Immuno-oncology latecomer GSK shows off PD-1 drug data